MX2013008188A - Composicion y metodo para tratar cancer. - Google Patents
Composicion y metodo para tratar cancer.Info
- Publication number
- MX2013008188A MX2013008188A MX2013008188A MX2013008188A MX2013008188A MX 2013008188 A MX2013008188 A MX 2013008188A MX 2013008188 A MX2013008188 A MX 2013008188A MX 2013008188 A MX2013008188 A MX 2013008188A MX 2013008188 A MX2013008188 A MX 2013008188A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- cancer
- treating cancer
- purified surface
- excreted protein
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000007644 Colony-Stimulating Factors Human genes 0.000 abstract 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 abstract 2
- 102000015696 Interleukins Human genes 0.000 abstract 2
- 108010063738 Interleukins Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001139—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describen composiciones farmacéuticas útiles como vacunas, las cuales contienen una superficie purificada o proteína excretada cualitativa o cuantitativamente asociada con un tipo de cáncer, al menos una interleucina (IL), y al menos un factor estimulante de colonia (CSF), en donde la superficie purificada o proteína excretada se proporciona en una cantidad suficiente para inducir una respuesta inmune en un individuo al que se le administra la composición. Dichas composiciones pueden ser utilizadas en métodos para el tratamiento de individuos que tienen cáncer, y para inducir una respuesta inmunoterapéutica en el mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/005,993 US8647627B2 (en) | 2011-01-13 | 2011-01-13 | Composition for a cancer vaccine |
PCT/US2012/020596 WO2012096870A1 (en) | 2011-01-13 | 2012-01-09 | Composition and method for treating cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013008188A true MX2013008188A (es) | 2013-12-02 |
MX343266B MX343266B (es) | 2016-10-31 |
Family
ID=45532060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013008188A MX343266B (es) | 2011-01-13 | 2012-01-09 | Composicion y metodo para tratar cancer. |
Country Status (11)
Country | Link |
---|---|
US (4) | US8647627B2 (es) |
EP (1) | EP2663324B1 (es) |
JP (2) | JP6118730B2 (es) |
CN (1) | CN103458917B (es) |
CA (1) | CA2824347A1 (es) |
EA (1) | EA028081B1 (es) |
ES (1) | ES2637637T3 (es) |
HK (1) | HK1188566A1 (es) |
MX (1) | MX343266B (es) |
UA (1) | UA108779C2 (es) |
WO (1) | WO2012096870A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014096367A1 (en) * | 2012-12-21 | 2014-06-26 | Servicio Andaluz De Salud | Expression of beta2-microglobulin as a prognostic marker for tumour immune escape and resistance to cancer immunotherapy and a diagnostic biomarker for patient selection for specific gene therapy |
CN103864939A (zh) * | 2014-03-26 | 2014-06-18 | 中国药科大学 | mGM-CSF/βhCG融合蛋白及其制备方法和应用 |
RU2719586C9 (ru) * | 2014-06-13 | 2020-05-21 | Алдар БУРИНБАЙАР | Пероральная композиция и способы иммунотерапии |
US20190086419A1 (en) * | 2016-03-09 | 2019-03-21 | Cézanne S.A.S. | Chromogranin a as a marker for bladder cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478556A (en) * | 1994-02-28 | 1995-12-26 | Elliott; Robert L. | Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor |
CA2246708C (en) * | 1996-02-16 | 2005-06-14 | Biomira Usa Inc. | Vaccine for b-cell malignancies |
US7517952B1 (en) * | 1997-02-25 | 2009-04-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
EP0974357A1 (en) | 1998-07-16 | 2000-01-26 | Schering-Plough | Chemokines as adjuvants of immune response |
IL150978A0 (en) * | 2000-02-18 | 2003-02-12 | New York Medical College | Nitroacridine/tumor inhibitor compositions |
US20060035375A1 (en) | 2004-08-16 | 2006-02-16 | Head Jonathan F | Method for selectively culturing epithelial or carcinoma cells |
US8435507B2 (en) | 2004-08-19 | 2013-05-07 | University Of Maryland | Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer |
US7919079B2 (en) * | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
US10722562B2 (en) * | 2008-07-23 | 2020-07-28 | Immudex Aps | Combinatorial analysis and repair |
-
2011
- 2011-01-13 US US13/005,993 patent/US8647627B2/en not_active Expired - Fee Related
-
2012
- 2012-01-09 CN CN201280005114.4A patent/CN103458917B/zh not_active Expired - Fee Related
- 2012-01-09 CA CA2824347A patent/CA2824347A1/en not_active Abandoned
- 2012-01-09 EP EP12701292.0A patent/EP2663324B1/en not_active Not-in-force
- 2012-01-09 JP JP2013549475A patent/JP6118730B2/ja active Active
- 2012-01-09 ES ES12701292.0T patent/ES2637637T3/es active Active
- 2012-01-09 MX MX2013008188A patent/MX343266B/es active IP Right Grant
- 2012-01-09 WO PCT/US2012/020596 patent/WO2012096870A1/en active Application Filing
- 2012-01-09 EA EA201370155A patent/EA028081B1/ru not_active IP Right Cessation
- 2012-09-01 UA UAA201309855A patent/UA108779C2/ru unknown
-
2013
- 2013-12-20 US US14/137,060 patent/US9211322B2/en not_active Expired - Fee Related
-
2014
- 2014-02-20 HK HK14101607.7A patent/HK1188566A1/zh not_active IP Right Cessation
-
2015
- 2015-11-16 US US14/942,517 patent/US20160136269A1/en not_active Abandoned
-
2016
- 2016-12-01 JP JP2016234153A patent/JP2017043635A/ja not_active Withdrawn
-
2019
- 2019-02-08 US US16/271,388 patent/US20190167788A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX343266B (es) | 2016-10-31 |
CA2824347A1 (en) | 2012-07-19 |
EP2663324B1 (en) | 2017-05-24 |
EP2663324A1 (en) | 2013-11-20 |
CN103458917B (zh) | 2016-01-20 |
WO2012096870A1 (en) | 2012-07-19 |
JP2017043635A (ja) | 2017-03-02 |
EA028081B1 (ru) | 2017-10-31 |
US20120282216A1 (en) | 2012-11-08 |
JP2014502636A (ja) | 2014-02-03 |
UA108779C2 (uk) | 2015-06-10 |
HK1188566A1 (zh) | 2014-05-09 |
US20160136269A1 (en) | 2016-05-19 |
US8647627B2 (en) | 2014-02-11 |
EA201370155A1 (ru) | 2013-11-29 |
US20140112884A1 (en) | 2014-04-24 |
JP6118730B2 (ja) | 2017-04-19 |
CN103458917A (zh) | 2013-12-18 |
US9211322B2 (en) | 2015-12-15 |
ES2637637T3 (es) | 2017-10-16 |
US20190167788A1 (en) | 2019-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500439A1 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
IN2014MN01781A (es) | ||
PH12016502132A1 (en) | Aryl-or heteroaryl-substituted benzene compounds | |
IN2015KN00414A (es) | ||
TW201712034A (en) | Anti-PD-L1 antibodies and their use to enhance t-cell function | |
PH12018500641A1 (en) | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
MX349096B (es) | Anticuerpos anti-pd-l1 y sus usos. | |
SG178991A1 (en) | Anti-gitr antibodies | |
MX2014008963A (es) | Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina. | |
IN2014MN00333A (es) | ||
WO2012145238A3 (en) | Methods for reducing an adverse immune response to a foreign antigen in human using cd4-binding molecules | |
EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
GB2496337A (en) | Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases | |
MX346094B (es) | Método de administración de vacunas. | |
NZ703597A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
MX343266B (es) | Composicion y metodo para tratar cancer. | |
SG194753A1 (en) | Induction of il-12 using immunotherapy | |
WO2013084070A3 (en) | Salmonella vaccine proteins | |
MX359476B (es) | Composiciones farmaceuticas para el tratamiento de tumores que expresan regf y gangliósido n-glicolil gm3 (neugcgm3). | |
UA106111C2 (uk) | Спосіб отримання людського інтерферону з використанням наночастинок оксиду церію | |
WO2012025831A3 (en) | Salmonella vaccine proteins | |
UA99801C2 (ru) | Белковая конструкция, которая включает модифицированный полипептид casb7439 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |